Exhibit 3

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, each of the undersigned Reporting Persons hereby agrees to the joint filing, along with all other such Reporting Persons, on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock, $0.001 par value, of Rigel Pharmaceuticals, Inc., and that this Agreement be included as an Exhibit to such joint filing. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.

IN WITNESS WHEREOF, each of the undersigned hereby executes this Agreement as of this 3rd day of August, 2007.
 

 
  
D. E. Shaw Composite Portfolios, L.L.C.
By:  D. E. Shaw & Co., L.L.C., as
        managing member
 
        By: /s/ Anne Dinning
               Anne Dinning
               Managing Director
  


   
D. E. Shaw & Co., L.L.C.
 
By: /s/ Anne Dinning
       Anne Dinning
       Managing Director
 
 
D. E. Shaw & Co., L.P.
 
By: /s/ Anne Dinning
       Anne Dinning
       Managing Director
  


 
  
David E. Shaw
 
By: /s/ Anne Dinning
       Anne Dinning
       Attorney-in-Fact for David E. Shaw